Management of People with Diabetes in Africa—Results from the International Diabetes Management Practices Study (IDMPS)
Authors: MBANYA JEAN CLAUDE , ASCHNER PABLO , GAGLIARDINO JUAN J. , ILKOVA HASAN M. , LAVALLE-GONZALEZ FERNANDO J. , RAMACHANDRAN AMBADY , KADDAHA GHAIDA , SHESTAKOVA MARINA V. , CHANTELOT JEAN-MARC , CHAN JULIANA C. 
Published: June 2018

The IDMPS is an observational survey on the management of people with type 1 (T1D) and type 2 (T2D) diabetes in the developing world. By 2045, Africa is predicted to experience a &gt;150% increase in the proportion of people with diabetes; however, there is a lack of data to support clinical practice and healthcare planning. We report demographics and disease characteristics of people enrolled in a cross-sectional analysis in 2015-16 from 231 physicians across 12 countries (Algeria, Cameroon, Democratic Republic of the Congo, Cote d’Ivoire, Egypt, Kenya, Madagascar, Morocco, Nigeria, Senegal, South Africa, Tunisia) (Table 1).

Most people with T2D were receiving metformin and sulfonylureas. Premixed insulins were the most common formulation, used by 46.5% of people with T1D, 67.4% of people with T2D treated with insulin alone, and 42.8% of people with T2D treated with an oral antihyperglycemic drug + insulin. Human insulin was used by 75.6%, 72.0%, and 53.8% of people in each group, respectively.

Most participants received some diabetes education, mostly delivered in hospital-based facilities; only 14% of people received a structured course of education. Only 13.8% and 9.7% of participants with T1D and T2D belonged to a patients’ association.

Characteristics of people with diabetes in Africa are like those observed in other regions, except for the preferred use of premixed human insulin.

Disclosure

J. Mbanya: Advisory Panel; Self; GlaxoSmithKline plc.. Speaker's Bureau; Self; Novo Nordisk A/S, Sanofi, Servier. P. Aschner: Other Relationship; Self; Sanofi. J.J. Gagliardino: Other Relationship; Self; Sanofi. H.M. Ilkova: Advisory Panel; Self; Abbott, Eli Lilly and Company, Novartis AG, Novo Nordisk A/S, Boehringer Ingelheim GmbH, Servier, Merck Sharp & Dohme Corp.. Speaker's Bureau; Self; AstraZeneca. Advisory Panel; Self; Medtronic, Roche Diabetes Care Health and Digital Solutions, Bilim İlac. F.J. Lavalle-Gonzalez: Advisory Panel; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Research Support; Self; Janssen Pharmaceuticals, Inc.. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc.. Consultant; Self; Novo Nordisk Inc.. Advisory Panel; Self; AstraZeneca. Speaker's Bureau; Self; AstraZeneca. Research Support; Self; AstraZeneca. Advisory Panel; Self; Merck Sharp & Dohme Corp.. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Advisory Panel; Self; Abbott. Speaker's Bureau; Self; Abbott. A. Ramachandran: None. G. Kaddaha: Other Relationship; Self; Sanofi. M.V. Shestakova: None. J. Chantelot: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. J.C. Chan: Consultant; Self; Bayer AG. Other Relationship; Self; Bayer AG. Consultant; Self; Sanofi. Other Relationship; Self; Sanofi, Eli Lilly and Company, Amgen Inc.. Consultant; Self; AstraZeneca, Merck & Co., Inc., Pfizer Inc.. Other Relationship; Self; Pfizer Inc.. Board Member; Self; Asia Diabetes Foundation. Stock/Shareholder; Self; GemVCare. Other Relationship; Self; Merck Sharp & Dohme Corp.. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Novartis AG, Eli Lilly and Company.